Reveal Multiple Pathways to Drug Resistance with the Single-Cell Intracellular Proteome Solution

Traditional Flow-Based Methods Provide Incomplete Picture of Therapeutic Resistance

Recently, we discussed how functional adaptations that lead to therapeutic resistance can go undetected by genomic profiling. To get a better characterization of these functional adaptations, many researchers have transitioned to using flow-based methods for cancer signaling research. However, flow cytometry-based methods still cannot provide the high multiplexing capabilities available with IsoPlexis’ Single-Cell Intracellular Proteome technology. Flow cytometry  identifies surface markers or detects a small number of  (1-4) blocked cytokines within the cell without detecting what is truly being secreted. Blocking cytokines within cells increases the risk of errors due to spectral overlap, and reduces the ability to multiplex cytokines reliably.

Create Pre-Clinical Meaning by Fully Characterizing Tumor Cell Pathways

Traditional flow-based methods may detect a single activated cancer signaling pathway, which in many cases becomes the target for cancer treatment. Once resistance to the treatment develops, the tumor returns, and additional experimental runs must be developed and performed to determine the source of resistance. Targeting the functional adaptations prior to activation with IsoPlexis’ solution can be an effective strategy for the prevention of resistance. By highly multiplexing for 15+ phosphoproteins simultaneously with the Single-Cell Intracellular Proteome solution, multiple resistance pathways can be detected simultaneously to determine the most effective target.

IsoPlexis’ solutions quantify the secretion capacity of single cells whereas cytokine profiling by flow cytometry typically relies on artificially disrupting protein transport within the cell to quantify cytokines blocked within. IsoPlexis’ pathway omics provides insights into the full network of cellular signaling pathways, generating invaluable data to overcome cancer therapy resistance and identify functional adaptive changes in cancer cells. IsoPlexis technology has linked secretion profiles to patient outcome with statistical significance in several retrospective studies, whereas flow cytometry and other bulk assays were not able to.

IsoPlexis’ intracellular signaling solution saves valuable time by requiring only sample loading—the remaining workflow is fully automated, allowing researchers to walk away to work on other vital tasks. While traditional methods could take weeks or months just to analyze the interactions between two pathways, IsoPlexis’ solution analyzes many pathway interactions and returns same-day data insights without the need for a data informatics expert. IsoPlexis’ Single-Cell Intracellular Proteome solution uniquely creates pre-clinical meaning with high multiplexing that identifies resistance targets that are missed by traditional methods.

Are you having trouble overcoming resistance in your therapeutic development? Speak with an expert to see how we can help.

Share This Article
Subscribe to Follow the Data

Weekly email to keep you at the forefront of single-cell & multiplexed proteomics.